Antibiotic Treatment, Mortality, Pneumococcal Conjugate Vaccine, Pneumococcal Infections
Conditions
Brief summary
After 7 then 13 valent pneumococcal conjugate vaccine (PCV) implementation in France in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We will describe the clinical characteristics of IPD, pneumococcus serotyping, underlying conditions and vaccination status.
Detailed description
For children under 18, hospitalized for IPD, the following data will be analyzed: risk factors, vaccination status, severity signs , treatment during hospitalization, biological analysis, the clinical location of the disease.
Interventions
None listed
Sponsors
Association Clinique Thérapeutique Infantile du val de Marne
Pfizer
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Days to 18 Years
Healthy volunteers
No
Inclusion criteria
* Isolate of Streptococcus pneumoniae from at least one blood culture, or pleural fluid, or joint fluid, or cerebrospinal fluid or other normally sterile body site, or if there is a positive blood polymerase chain reaction (PCR).
Exclusion criteria
* Pneumococcal strain not transmetted to National Reference Center for Pneumococci or to Regional Pneumococci Observatory
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Severity of invasive pneumococcal disease | before hospital discharge | Number of severe cases according to age and pneumococcal serotypes distribution |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Impact of vaccines | before hospital discharge | Number of invasive pneumococcal disease according to vaccine serotypes |
Countries
France
Contacts
CONTACTLevy Corinne
CONTACTBechet Stephane
STUDY_DIRECTORLevy Corinne
Association Clinique Thérapeutique Infantile du val de Marne
PRINCIPAL_INVESTIGATORCohen Robert
Association Clinique Thérapeutique Infantile du val de Marne
Outcome results
None listed